ACB - Aurora Cannabis Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Edmonton,
Canada
Type: Equity
ACB price evolution
ACB
| (in millions $) | 30 Oct 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $43.32 | $39.72 | $32.55 | |
| Inventory | $143.96 | $139.23 | $124.85 | |
| Total current assets | $406.53 | $387.98 | $399.31 | |
| Long term investments | ||||
| Property, plant & equipment | $295.64 | $306.84 | $307.52 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $817.17 | $818.37 | $832.19 | |
| Current liabilities | ||||
| Accounts payable | $22.71 | $14.68 | $13.78 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $107.38 | $117.97 | $172 | |
| Long term debt | $78.36 | $79.96 | $76.93 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $300.72 | $314.59 | $356.46 | |
| Shareholders' equity | ||||
| Retained earnings | -$6124.38 | -$6097.3 | -$6083.61 | |
| Other shareholder equity | -$297.94 | -$297.81 | -$296.92 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2022 | 30 Jul 2021 | 29 Jul 2020 | 29 Jul 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $344.13 | $120.92 | $165.25 | |
| Short term investments | ||||
| Net receivables | $47.05 | $44.09 | $40.34 | $84.84 |
| Inventory | $139.93 | $107.5 | $117.25 | $124.98 |
| Total current assets | $745.12 | $519.8 | $313.7 | $501.65 |
| Long term investments | ||||
| Property, plant & equipment | $233.47 | $473.12 | $705.62 | $578.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1513.46 | $1761.82 | $3654.64 | |
| Total investments | ||||
| Total assets | $1084.36 | $2033.25 | $2075.52 | $4156.29 |
| Current liabilities | ||||
| Accounts payable | $13.86 | $45.52 | $85.88 | $136.73 |
| Deferred revenue | $3.25 | $2.63 | $1.12 | |
| Short long term debt | ||||
| Total current liabilities | $145.23 | $90.84 | $203.4 | $329.59 |
| Long term debt | $236.49 | $358.61 | $62.41 | $96.29 |
| Total noncurrent liabilities | $351.78 | $286.64 | $510.9 | |
| Total debt | ||||
| Total liabilities | $422.51 | $442.62 | $490.04 | $840.49 |
| Shareholders' equity | ||||
| Retained earnings | -$5794.68 | -$3373.04 | -$2678.78 | -$214.23 |
| Other shareholder equity | -$298.1 | -$51.14 | -$49.33 | $0.43 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $50.22 | $50.43 | ||
| Cost of revenue | ||||
| Gross Profit | -$22.24 | -$52.93 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $64.57 | $57.61 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$1.36 | -$0.2 | ||
| Interest expense | $1.34 | -$13.32 | ||
| Net income | ||||
| Net income | -$618.79 | -$1012.18 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 30 Jul 2021 | 29 Jul 2020 | 29 Jul 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $221.34 | $191.44 | $207.95 | $187.27 |
| Cost of revenue | ||||
| Gross Profit | -$97.45 | -$16.83 | -$25.01 | $120.71 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $247.98 | $204.21 | $342.01 | $358.62 |
| Operating income | -$220.77 | -$366.06 | -$237.35 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$2.14 | -$4.93 | -$62.19 | -$22.89 |
| Interest expense | -$6.68 | $51.86 | $57.81 | $30.99 |
| Net income | ||||
| Net income | -$1717.62 | -$542.59 | -$2468.19 | -$219.67 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$41.93 | -$36.6 | $3.14 | -$9.35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$9.63 | $147.78 | $85.74 | -$41.17 |
| Effect of exchange rate | $14.17 | $15.01 | $2.76 | $5.7 |
| Change in cash and equivalents | -$68.53 | $16.35 | $8.44 | -$89.05 |
| (in millions $) | 30 Jul 2022 | 30 Jul 2021 | 29 Jul 2020 | 29 Jul 2019 |
|---|---|---|---|---|
| Net income | -$541.33 | -$2460.85 | -$225.02 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$164.38 | -$251.98 | -$145.2 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$36.6 | -$21 | -$186.01 | -$235.88 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $147.78 | $407.44 | $434.36 | $451.33 |
| Effect of exchange rate | $15.01 | -$19.67 | -$4.23 | $2.22 |
| Change in cash and equivalents | $16.35 | $202.39 | -$7.86 | $72.47 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |